Stability of meropenem in plasma versus dried blood spots (DBS).
Autor: | Martens-Lobenhoffer J; Institute of Clinical Pharmacology, Otto-von-Guericke University, Magdeburg, Germany. Electronic address: jens.martens-lobenhoffer@med.ovgu.de., Monastyrski D; Institute of Clinical Pharmacology, Otto-von-Guericke University, Magdeburg, Germany., Tröger U; Institute of Clinical Pharmacology, Otto-von-Guericke University, Magdeburg, Germany., Bode-Böger SM; Institute of Clinical Pharmacology, Otto-von-Guericke University, Magdeburg, Germany. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2019 Jun 05; Vol. 170, pp. 279-284. Date of Electronic Publication: 2019 Mar 25. |
DOI: | 10.1016/j.jpba.2019.03.055 |
Abstrakt: | Meropenem, a beta-lactam antibiotic belonging to the group of carbapenems, is widely used in the treatment of serious and complicated infections. Therapeutic drug monitoring (TDM) is strongly recommended to achieve therapeutic success, but the limited stability of the drug in plasma makes transport between clinic and laboratory difficult. The aim of this study was to investigate whether the stability of meropenem was improved in dried blood spots (DBS) and whether sample transport between clinic and laboratory could be simplified by using this medium. Meropenem was quantified in DBS punch-out discs after extraction into acetonitrile - water (70:30 v:v) containing the internal standard D (Copyright © 2019 Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |